Robotic Assisted Endovascular Systems Market Predicts US$214.7 Million by 2033

The global robotic assisted endovascular systems market is anticipated to grow rapidly, with a projected market value of US$ 94.0 million in 2023 and an anticipated CAGR of 8.6% over the forecast period. By 2033, the market is estimated to be valued US$ 214.7 million.

The Robotic Assisted Endovascular Systems Market involves the application of cutting-edge robotic technology in endovascular procedures, which are minimally invasive treatments conducted within blood vessels. These procedures primarily address a range of conditions, including cardiovascular diseases, peripheral artery diseases, aneurysms, and various vascular disorders.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17601

Several factors are driving the escalating demand for Robotic Assisted Endovascular Systems:

1. Growing Disease Prevalence:The increasing incidence of cardiovascular diseases, peripheral artery diseases, and other vascular disorders is fueling the demand for advanced treatment options.

2. Robotic Technology Advancements:Ongoing developments in robotic technology are equipping robotic-assisted endovascular systems with enhanced capabilities.

3. Surgeon Adoption:An increasing number of surgeons are recognizing the potential benefits of integrating robotic systems into endovascular procedures, seeking state-of-the-art equipment and technology to enhance their efficiency and improve patient outcomes.

The Robotic Assisted Endovascular Systems Market’s growth signifies a promising shift towards advanced, minimally invasive treatments for vascular disorders, providing both patients and healthcare professionals with innovative and efficient solutions.

Key Players:

Siemens Healthcare
Stereotaxis, Inc

Key Developments in the Robotic Assisted Endovascular Systems Market:

Cathbot Robot Co., Ltd. (Shanghai Cathbot), developed a vascular interventional surgical robot. In August 2022, the company announced the conclusion of its clinical trial, making it the first robotic system to have finished a multicenter clinical trial in China, for vascular intervention. Further, the company is a collaboration between French company Robocath S.A.S (Robocath), R-ONETM and Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot)
In December 2018, 48 CorPath GRX Systems were deployed in hospitals around the United States, and four were installed abroad.

Robotic Assisted Endovascular Systems Market Segmentation:

By Product: